News & Updates
Showing Neurology articles
Showing
Show Multimedia Only

Donanemab delays Alzheimer's disease progression over 3 years
04 Jun 2026
byKanas Chan
Donanemab administered for a limited duration continues to slow clinical progression in patients with early symptomatic Alzheimer’s disease (AD) over 3 years, according to Professor Chaur-Jong Hu of the Department of Neurology, Taipei Medical University, who spoke at Advances in Medicine (AIM) 2026.
04 Jun 2026







